Denny Lanfear

Person

Last mentioned: Mar 8, 2026

Timeline

  1. Q4 2025 Preview

    Analysts set expectations for oncology-driven revenue growth.

  2. Loqtorzi Launch

    Full commercial ramp-up of the first-in-class PD-1 for NPC.

  3. Yusimry Divestiture

    Sale of adalimumab biosimilar to HK King-Friend for $40M.

  4. Cimerli Divestiture

    Coherus sells its ranibizumab biosimilar to Sandoz for $170M.

Stories mentioning Denny Lanfear 1

market-trends Neutral

Coherus BioSciences Q4 Preview: Oncology Pivot and Udenyca Growth in Focus

Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.

2 sources